KRAS and cancer: KRAS mutations are found in 10–30% of well-differentiated endometrial cancers and are known for their role as an early checkpoint in the transition from hyperplasia to cancer [41, 42] and as markers of invasive potential in well-differentiated tumours [42, 43].